Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 93 entries
Sorted by: Best Match Show Resources per page
Will drug companies' price-transparency efforts fall short?.

The Lancet. Oncology

Furlow B.
PMID: 28215927
Lancet Oncol. 2017 Mar;18(3):288. doi: 10.1016/S1470-2045(17)30122-5. Epub 2017 Feb 17.

No abstract available.

Cite
Furlow B. Will drug companies' price-transparency efforts fall short?. Lancet Oncol. 2017;18(3):288doi: 10.1016/S1470-2045(17)30122-5.
Furlow, B. (2017). Will drug companies' price-transparency efforts fall short?. The Lancet. Oncology, 18(3), 288. https://doi.org/10.1016/S1470-2045(17)30122-5
Furlow, Bryant. "Will drug companies' price-transparency efforts fall short?." The Lancet. Oncology vol. 18,3 (2017): 288. doi: https://doi.org/10.1016/S1470-2045(17)30122-5
Furlow B. Will drug companies' price-transparency efforts fall short?. Lancet Oncol. 2017 Mar;18(3):288. doi: 10.1016/S1470-2045(17)30122-5. Epub 2017 Feb 17. PMID: 28215927.
Copy Download .nbib Format: NLM
Drug Pricing in South Korea.

Applied health economics and health policy

Kwon HY, Godman B.
PMID: 28138932
Appl Health Econ Health Policy. 2017 Aug;15(4):447-453. doi: 10.1007/s40258-017-0307-0.

Between 2000 and 2013, spending on medicines in Korea increased by 275.3%. In order to curb this trend, several pricing policies and measures were introduced. This study reviews these policies and their implications based on pricing regulations as well...

Cite
Kwon HY, Godman B. Drug Pricing in South Korea. Appl Health Econ Health Policy. 2017;15(4):447-453doi: 10.1007/s40258-017-0307-0.
Kwon, H. Y., & Godman, B. (2017). Drug Pricing in South Korea. Applied health economics and health policy, 15(4), 447-453. https://doi.org/10.1007/s40258-017-0307-0
Kwon, Hye-Young, and Godman, Brian. "Drug Pricing in South Korea." Applied health economics and health policy vol. 15,4 (2017): 447-453. doi: https://doi.org/10.1007/s40258-017-0307-0
Kwon HY, Godman B. Drug Pricing in South Korea. Appl Health Econ Health Policy. 2017 Aug;15(4):447-453. doi: 10.1007/s40258-017-0307-0. PMID: 28138932.
Copy Download .nbib Format: NLM
Policies for biosimilar uptake in Europe: An overview.

PloS one

Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S.
PMID: 29284064
PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017.

BACKGROUND: Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.OBJECTIVES: The aim of this article is to provide an overview of different initiatives and policies that...

Cite
Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017;12(12):e0190147doi: 10.1371/journal.pone.0190147.
Moorkens, E., Vulto, A. G., Huys, I., Dylst, P., Godman, B., Keuerleber, S., Claus, B., Dimitrova, M., Petrova, G., Sović-Brkičić, L., Slabý, J., Šebesta, R., Laius, O., Karr, A., Beck, M., Martikainen, J. E., Selke, G. W., Spillane, S., McCullagh, L., Trifirò, G., Vella Bonanno, P., Mack, A., Fogele, A., Viksna, A., Władysiuk, M., Mota-Filipe, H., Meshkov, D., Kalaba, M., Mencej Bedrač, S., Fürst, J., Zara, C., Skiöld, P., Magnússon, E., & Simoens, S. (2017). Policies for biosimilar uptake in Europe: An overview. PloS one, 12(12), e0190147. https://doi.org/10.1371/journal.pone.0190147
Moorkens, Evelien, et al. "Policies for biosimilar uptake in Europe: An overview." PloS one vol. 12,12 (2017): e0190147. doi: https://doi.org/10.1371/journal.pone.0190147
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017. PMID: 29284064; PMCID: PMC5746224.
Copy Download .nbib Format: NLM
Towards a balanced value business model for personalized medicine: an outlook.

Pharmacogenomics

Koelsch C, Przewrocka J, Keeling P.
PMID: 23252951
Pharmacogenomics. 2013 Jan;14(1):89-102. doi: 10.2217/pgs.12.192.

Novel targeted drugs, mainly in oncology, have commanded substantial price premiums in the recent past. Consequently, the attention of pharmaceutical companies has shifted away from the traditional low-price and high-volume blockbuster business model to drugs that command high, and...

Cite
Koelsch C, Przewrocka J, Keeling P. Towards a balanced value business model for personalized medicine: an outlook. Pharmacogenomics. 2013;14(1):89-102doi: 10.2217/pgs.12.192.
Koelsch, C., Przewrocka, J., & Keeling, P. (2013). Towards a balanced value business model for personalized medicine: an outlook. Pharmacogenomics, 14(1), 89-102. https://doi.org/10.2217/pgs.12.192
Koelsch, Christof, et al. "Towards a balanced value business model for personalized medicine: an outlook." Pharmacogenomics vol. 14,1 (2013): 89-102. doi: https://doi.org/10.2217/pgs.12.192
Koelsch C, Przewrocka J, Keeling P. Towards a balanced value business model for personalized medicine: an outlook. Pharmacogenomics. 2013 Jan;14(1):89-102. doi: 10.2217/pgs.12.192. PMID: 23252951.
Copy Download .nbib Format: NLM
Time to stop skyrocketing drug costs.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Guharoy R.
PMID: 29371187
Am J Health Syst Pharm. 2018 Feb 01;75(3):91-92. doi: 10.2146/ajhp170599.

No abstract available.

Cite
Guharoy R. Time to stop skyrocketing drug costs. Am J Health Syst Pharm. 2018;75(3):91-92doi: 10.2146/ajhp170599.
Guharoy, R. (2018). Time to stop skyrocketing drug costs. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 75(3), 91-92. https://doi.org/10.2146/ajhp170599
Guharoy, Roy. "Time to stop skyrocketing drug costs." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol. 75,3 (2018): 91-92. doi: https://doi.org/10.2146/ajhp170599
Guharoy R. Time to stop skyrocketing drug costs. Am J Health Syst Pharm. 2018 Feb 01;75(3):91-92. doi: 10.2146/ajhp170599. PMID: 29371187.
Copy Download .nbib Format: NLM
Value-Based Cancer Care.

The New England journal of medicine

Young RC.
PMID: 26580243
N Engl J Med. 2015 Dec 31;373(27):2593-5. doi: 10.1056/NEJMp1508387. Epub 2015 Nov 18.

No abstract available.

Cite
Young RC. Value-Based Cancer Care. N Engl J Med. 2015;373(27):2593-5doi: 10.1056/NEJMp1508387.
Young, R. C. (2015). Value-Based Cancer Care. The New England journal of medicine, 373(27), 2593-5. https://doi.org/10.1056/NEJMp1508387
Young, Robert C. "Value-Based Cancer Care." The New England journal of medicine vol. 373,27 (2015): 2593-5. doi: https://doi.org/10.1056/NEJMp1508387
Young RC. Value-Based Cancer Care. N Engl J Med. 2015 Dec 31;373(27):2593-5. doi: 10.1056/NEJMp1508387. Epub 2015 Nov 18. PMID: 26580243.
Copy Download .nbib Format: NLM
Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence.

Health affairs (Project Hope)

Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO.
PMID: 28373337
Health Aff (Millwood). 2017 Apr 01;36(4):706-713. doi: 10.1377/hlthaff.2016.1213.

Global biopharmaceutical companies are increasingly establishing access-to-medicines (AtM) initiatives in low- and middle-income countries. We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact...

Cite
Rockers PC, Wirtz VJ, Umeh CA, et al. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Health Aff (Millwood). 2017;36(4):706-713doi: 10.1377/hlthaff.2016.1213.
Rockers, P. C., Wirtz, V. J., Umeh, C. A., Swamy, P. M., & Laing, R. O. (2017). Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Health affairs (Project Hope), 36(4), 706-713. https://doi.org/10.1377/hlthaff.2016.1213
Rockers, Peter C, et al. "Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence." Health affairs (Project Hope) vol. 36,4 (2017): 706-713. doi: https://doi.org/10.1377/hlthaff.2016.1213
Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Health Aff (Millwood). 2017 Apr 01;36(4):706-713. doi: 10.1377/hlthaff.2016.1213. PMID: 28373337.
Copy Download .nbib Format: NLM
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?.

PharmacoEconomics

Mestre-Ferrandiz J, Zozaya N, Alcalá B, Hidalgo-Vega Á.
PMID: 30198061
Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4.

For medicines with different valued indications (uses), multi-indication pricing implies charging different prices for different uses. In this article, we assess how multi-indication pricing could help achieve overall strategic objectives of pricing controls, summarise its advantages and disadvantages (vs....

Cite
Mestre-Ferrandiz J, Zozaya N, Alcalá B, et al. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. Pharmacoeconomics. 2018;36(12):1407-1420doi: 10.1007/s40273-018-0716-4.
Mestre-Ferrandiz, J., Zozaya, N., Alcalá, B., & Hidalgo-Vega, �. �. (2018). Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. PharmacoEconomics, 36(12), 1407-1420. https://doi.org/10.1007/s40273-018-0716-4
Mestre-Ferrandiz, Jorge, et al. "Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?." PharmacoEconomics vol. 36,12 (2018): 1407-1420. doi: https://doi.org/10.1007/s40273-018-0716-4
Mestre-Ferrandiz J, Zozaya N, Alcalá B, Hidalgo-Vega Á. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4. PMID: 30198061.
Copy Download .nbib Format: NLM
Research and Development Costs of New Drugs.

JAMA

Dominguez LW, Willis JS.
PMID: 32749484
JAMA. 2020 Aug 04;324(5):516. doi: 10.1001/jama.2020.8645.

No abstract available.

Cite
Dominguez LW, Willis JS. Research and Development Costs of New Drugs. JAMA. 2020;324(5):516doi: 10.1001/jama.2020.8645.
Dominguez, L. W., & Willis, J. S. (2020). Research and Development Costs of New Drugs. JAMA, 324(5), 516. https://doi.org/10.1001/jama.2020.8645
Dominguez, Luis W, and Willis, Joel S. "Research and Development Costs of New Drugs." JAMA vol. 324,5 (2020): 516. doi: https://doi.org/10.1001/jama.2020.8645
Dominguez LW, Willis JS. Research and Development Costs of New Drugs. JAMA. 2020 Aug 04;324(5):516. doi: 10.1001/jama.2020.8645. PMID: 32749484.
Copy Download .nbib Format: NLM
How biosimilars will impact costs and care in oncology.

Clinical advances in hematology & oncology : H&O

Lyman GH.
PMID: 31730579
Clin Adv Hematol Oncol. 2019 Oct;17(10):544-547.

No abstract available.

Cite
Lyman GH. How biosimilars will impact costs and care in oncology. Clin Adv Hematol Oncol. 2019;17(10):544-547
Lyman, G. H. (2019). How biosimilars will impact costs and care in oncology. Clinical advances in hematology & oncology : H&O, 17(10), 544-547.
Lyman, Gary H. "How biosimilars will impact costs and care in oncology." Clinical advances in hematology & oncology : H&O vol. 17,10 (2019): 544-547.
Lyman GH. How biosimilars will impact costs and care in oncology. Clin Adv Hematol Oncol. 2019 Oct;17(10):544-547. PMID: 31730579.
Copy Download .nbib Format: NLM
Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?.

Tropical doctor

Meher BR, Padhy BM.
PMID: 32036770
Trop Doct. 2020 Apr;50(2):157-159. doi: 10.1177/0049475520903644. Epub 2020 Feb 09.

The concept of indication-specific pricing (ISP) of drugs means that the cost of a drug will vary depending on the reasons for its use. ISP is a novel concept and its beneficial or detrimental effects are unknown. Experience from...

Cite
Meher BR, Padhy BM. Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Trop Doct. 2020;50(2):157-159doi: 10.1177/0049475520903644.
Meher, B. R., & Padhy, B. M. (2020). Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Tropical doctor, 50(2), 157-159. https://doi.org/10.1177/0049475520903644
Meher, Bikash R, and Padhy, Biswa M. "Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?." Tropical doctor vol. 50,2 (2020): 157-159. doi: https://doi.org/10.1177/0049475520903644
Meher BR, Padhy BM. Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Trop Doct. 2020 Apr;50(2):157-159. doi: 10.1177/0049475520903644. Epub 2020 Feb 09. PMID: 32036770.
Copy Download .nbib Format: NLM
When the Cost of Medications Keeps Patients From Taking Them.

Managed care (Langhorne, Pa.)

Kelley T.
PMID: 29989904
Manag Care. 2018 Jun;27(6):12-16.

Even the most effective drug is useless if its cost prevents people from using it. Today's high drug prices are pushing more patients into nonadherence. This can impair or shorten life, and that's toxic for a system that has...

Cite
Kelley T. When the Cost of Medications Keeps Patients From Taking Them. Manag Care. 2018;27(6):12-16
Kelley, T. (2018). When the Cost of Medications Keeps Patients From Taking Them. Managed care (Langhorne, Pa.), 27(6), 12-16.
Kelley, Timothy. "When the Cost of Medications Keeps Patients From Taking Them." Managed care (Langhorne, Pa.) vol. 27,6 (2018): 12-16.
Kelley T. When the Cost of Medications Keeps Patients From Taking Them. Manag Care. 2018 Jun;27(6):12-16. PMID: 29989904.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 93 entries